HER2 Positive Gastric Cancer Market

Market Insights on HER2 positive gastric cancer covering sales outlook, demand forecast & up-to-date key trends

HER2 Positive Gastric Cancer Market Therapy, Stage, End-User & Region | Forecast 2023 to 2033

HER2 Positive Gastric Cancer Market Snapshot (2023 to 2033)

The global HER2-positive gastric cancer market is currently valued at US$ 1261.8 Million in 2023 and is anticipated to expand at a CAGR of 3.5%. Owing to the technological advances in healthcare the market is likely to propel to US$1779.8 Million by 2033.

“The increase in disease burden and approval of pipeline candidates are likely to drive the growth of the HER2 positive market in the forecast period.”

Report Attribute	Details
Expected Market Value (2023)	US$ 1261.8 Million
Projected Forecast Value (2033)	US$ 1779.8 Million
Global Growth Rate (2023 to 2033)	3.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

HER2 Positive Gastric Cancer Market Revenue Analysis 2017 to 2022 vs. Future Outlook 2023 to 2033

The HER2-positive gastric cancer market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 3.5% in the above-mentioned forecast period.

The stomach cancer cells have too much of a growth-promoting protein called HER2 on their surface. Cancers with increased levels of HER2 are called HER2-positive. Drugs that target the HER2 protein can often be helpful in treating these cancers.

Over the coming years, the soaring emphasis on the development of more effective treatment procedures and advanced drugs is projected to foster the HER2-positive gastric cancer market.

What Market Trends Are Influencing the HER2 Positive Gastric Cancer Market?

The Approval of New Targeted and Immunotherapy Drugs Is Expected to Fuel the Market Growth During the Forecast Period

The increasing incidence of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the globe. Major drivers for the stomach cancer market are treatment advancements, combination therapies, an increasing number of cancer treatment centers

Quick approvals from the regulatory authorities regarding HER2-positive gastric cancer drugs may bring immense growth prospects for the gastric cancer drugs market. Research and development activities play an important role in developing novel drugs and therapies.

For instance, in January 2021, the US FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers.

Increasing Healthcare Awareness to Boost the Market Growth

Health awareness amongst the population is rising which results in the prediction of drugs boosting the market growth. The innovative launches in medications for treating HER 2-positive gastric cancer are expected to prompt the market simultaneously.

Different researchers are investing in launching drugs that benefit the market. This creates more opportunities in the market. An increase in the incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma; a rise in alcohol consumption, a surge in smoking, and an increase in the geriatric population are anticipated to boost the growth of the global HER 2 positive gastric cancer testing market during the forecast period.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Factors Are Restraining the Growth of the HER2 Positive Gastric Cancer Market?

Stringent Government Regulation for Drug Approval May Restrain The Market Growth

Despite a positive growth trajectory, the global HER2-positive Gastric Cancer market is facing various challenges that are likely to pose a threat to its growth during the forecast period.

The lack of understanding of intratumoral heterogeneity, erosion in innovator sales, like the launch of biosimilars, and lack of universal guidelines for the assessment of HER2 overexpression or amplification may restrain the growth of the market during the forecast period.

The lack of adequate financial assistance from health insurance policies and stringent regulatory procedures for approving the complex nature of radiation devices are the major factors that can hamper the gastric cancer market growth over the forecast period.

Country-Wise Insights

What Makes the US an Attractive Market for HER2 Positive Gastric Cancer?

Increasing cancer cases in the region drive the market growth in North America

North America dominated the market and accounted for the largest revenue share of around 3.4% in 2023. The rising prevalence of gastric cancer is driving the growth of the HER2-positive gastric cancer market in North America.

Gastric cancer is the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease.1,2 Approximately one in five gastric cancers are considered HER2 positive. An estimated 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to more than 11,000 deaths in the US in 2020.

Thus, the increasing number of gastric cancer cases in the region is expected to rise the demand for effective therapies for treating patients with gastric cancer which in turn is anticipated to fuel the market growth over the forecast period.

The rising adoption of targeted cancer therapy and the availability of advanced technology in cancer research and treatment centers boost the market growth in the region.

For instance, in May 2020 AstraZeneca and Daiichi Sankyo Company, Limited has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

Why is the HER2 Positive Gastric Cancer Market in Europe Expected to Be Highly Opportunistic?

Increase in Significant Research and Development Investments in Healthcare to Boost the Market Growth

Europe is estimated to witness considerable growth during the forecast period due to increasing investments in the development of advanced treatment options and the rising target patient population.

Furthermore, the rising company activities in conducting clinical trials for developing effective drugs for patients suffering from HER2-positive gastric cancer as well as increasing product launches and approvals in the region are expected to fuel the market growth.

For instance, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

Which Factors Are Supporting Growth of the HER2 Positive Gastric Cancer Market in Asia Pacific?

Advancement in Healthcare to Propel the Market Growth

Asia Pacific is anticipated to expand at the fastest CAGR of % during the forecast period. Rapid growth in global demand for drugs has encouraged major drug manufacturers to set up facilities for manufacturing Research and Development in this region. Initiatives undertaken by various organizations to create awareness, educate people, and raise funds for the disease are anticipated to propel regional growth.

Furthermore, advancements in healthcare infrastructure, rising government spending on healthcare policies, and the presence of important members in Asia Pacific all contribute to the growth of the global HER2-positive gastric cancer market.

Country-wise Forecast CAGRs for the HER2 Positive Gastric Cancer Market

The UK	3.3%
India	3.1%
South Korea	3.3%
China	3.2 %
The US	3.4 %

Category wise Insights

Based on Therapy Type, Which Is the Most Prominent Segment in The HER 2 Positive Gastric Cancer Market?

Targeted Therapy Segment remains dominant among other types

Based on the therapy, the targeted therapy accounted for the largest market share in 2023. This is attributed to the increased adoption of targeted therapy along with the chemotherapy and rise in awareness regarding combination therapies for gastric cancer. HER-2 inhibitor trastuzumab is the only molecular targeted drug approved by the US Food and Drug Administration (FDA) for the first-line treatment of HER-2-positive advanced gastric cancer. The segment held a revenue share of over 55.4% in 2023

Therefore, the rising prevalence of gastric cancer and increased usage of targeted therapy in combination with different other therapies has fostered the growth of this segment in the past few years.

Immunotherapy is estimated to be the fastest-growing segment during the forecast period. The rising awareness among patients regarding the effectiveness and benefits of immunotherapy over chemotherapy is expected to boost the growth of this segment. The growing focus of the manufacturers and the active participation of the authorities like the FDA and EMA in the approval of immunotherapy drugs is expected to augment the demand for immunotherapy drugs for the treatment of Her2-positive gastric cancer.

By End-User, Which Segment Generates High Revenue in HER2 Positive Gastric Cancer Market?

Hospital and Speciality Clinics Dominated the Market

The Hospital and speciality clinics segment dominated the Her 2 positive gastric cancer therapy market in 2023 with a revenue share of over 35.0%. Initiatives by regional governments to develop healthcare infrastructure is expected to drive the segment growth during the forecast period. Based on the end-user, the market has been segmented into hospitals and speciality and ambulatory surgery centres.

The ambulatory surgery centre segment accounted for the second-largest share in 2021. Most patients with gastric cancer undergo inpatient administration of treatment in developing nations. This is one of the major factors fueling the growth of this segment.

Start-up Scenario

How do New Entrants Contribute to the HER2 Positive Gastric Cancer Market?

With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the HER2-positive Gastric Cancer market.

Some of the start-ups in the HER2-positive Gastric Cancer market include-

Novocodex Biopharmaceuticals - Nvocode is a developer of antibodies for the treatment of cancer. The company is designing biopharmaceutical anti-HER2 (product code: NCB001), a monoclonal antibody-conjugated drug through non-natural amino acid insertion technology for the coupling of toxins on mAb. It is used for the treatment of HER2, positive recurrent breast cancer, and gastric cancer.
VCell provides a biosimilar product for curing autoimmune diseases. The products provided are Remsima mainly used to treat autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis, Truxima anti-tumor biosimilar product mainly used to treat non-Hodgkin's lymphoma and other hematological tumors and rheumatoid arthritis. Herzuma is mainly used for the treatment of HER2-positive breast and gastric cancer.
Abscint, developer of radiolabelled single domain antibodies to diagnose cancer and cardiac diseases, offers ABSCINT-HER2 for the detection of HER2 positive cells in the brains and ABSCINT-206 for the detection of immune cells in granuloma CD-206 positive macrophages in the heart.
ASLAN Pharmaceuticals is an oncology-focused company developing a portfolio of targeted drugs, focusing on gastric, bile duct, and breast cancers. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced compounds are ASLAN001 which is a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer, and gastric cancer, and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET receptor tyrosine kinases, being developed in gastric and breast cancer.

Competitive Landscape

Key pharmaceutical companies that are working efficiently in the HER2-positive Gastric Cancer space include names like AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG, and others.

The manufacturers are involved in the production of HER2-positive Gastric Cancer in a larger capacity. Research and innovation are also conducted to launch innovative products for HER2-positive Gastric Cancer.

Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.

In May 2021, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
On September 20, 2022 - CytoReason announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs.
In December 2022 - Shanghai Henlius Biotech, Inc. announced that the first patient has been dosed in a phase 1 clinical trial (NCT05394168) of the company’s HLX53, an anti-TIGIT Fc fusion protein, for the treatment of advanced or metastatic solid tumors or lymphomas in China.

Report Scope

Report Attribute	Details
Growth Rate	CAGR from 2023 to 2033
Expected Market Value (2023)	US$1261.8 Million
ProjectedForecast Value (2033)	US$1779.8 Million
Base Year for Estimation	2022
Historical Data	2017 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million & CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis
Segments Covered	Therapy Stage End-user Regions
Regions Covered	North America Latin America Western Europe Eastern Europe Asia-Pacific Middle East & Africa (MEA)
Key Countries Profiled	The US Canada Brazil Mexico Benelux France Germany Italy Nordic Spain The UK Poland Russia India Malesia Singapore Thailand Australia New Zealand GCC South Africa Israel
Key Companies Profiled	AstraZeneca Bayer Bristol-Myers Squibb Ono Pharmaceutical Co. Ltd Hutchison Medipharma LintonPharm Shanghai Henlius Biotech Sanofi Pfizer Novartis AG
Customization	Available Upon Request

Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey

HER2 Positive Gastric Cancer Market by Therapy:

Chemotherapy
Immunotherapy
Radiation Therapy
Targeted Therapy

HER2 Positive Gastric Cancer Market by Stage:

Stage I
Stage II
Stage III
Stage IV

HER2 Positive Gastric Cancer Market by End-User:

Ambulatory surgery centers,
Hospitals and Specialty clinics
Others

HER2 Positive Gastric Cancer Market by Region:

North America
Latin America
Western Europe
Eastern Europe
Asia-Pacific
Middle East & Africa (MEA)

Frequently Asked Questions

What is the expected valuation of HER2 positive gastric cancer market?

The global Her 2 positive gastric cancer market is likely to reach a valuation of US$ 1261.8 Million by the end of 2023.

Who are the key players in HER2 positive gastric cancer market?

AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm are some of the key players in the global HER2 positive gastric cancer market

What are the future prospects for HER2 positive gastric cancer market sales?

Sales of HER2 positive gastric cancer market are likely to expand at 3.5% CAGR through 2033.

Which are the top 5 countries driving demand for biopharma plastics?

The US, Canada, Japan, China, & Germany are expected to drive most of the demand for HER2 positive gastric cancer market.

What will be the global HER2 positive gastric cancer market revenue total by 2033?

By the end of 2033, the global market for HER2-positive gastric cancer market is predicted to reach a valuation of US$1779.8 Million

Table of Content

1. Executive Summary | HER2 Positive Gastric Cancer Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033

        5.3.1. Chemotherapy

        5.3.2. Immunotherapy

        5.3.3. Radiation Therapy

        5.3.4. Targeted Therapy

        5.3.5. Surgery

    5.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Stage, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Stage, 2023 to 2033

        6.3.1. Stage I

        6.3.2. Stage II

        6.3.3. Stage III

        6.3.4. Stage IV

    6.4. Y-o-Y Growth Trend Analysis By Stage, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Stage, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        7.3.1. Ambulatory Surgery Centers

        7.3.2. Hospitals and Specialty Clinics

        7.3.3. Others

    7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. Asia-Pacific

        8.3.6. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The US

            9.2.1.2. Canada

        9.2.2. By Therapy

        9.2.3. By Stage

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Therapy

        9.3.3. By Stage

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Therapy

        10.2.3. By Stage

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy

        10.3.3. By Stage

        10.3.4. By End User

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Benelux

            11.2.1.2. France

            11.2.1.3. Germany

            11.2.1.4. Italy

            11.2.1.5. Nordic

            11.2.1.6. Spain

            11.2.1.7. The UK

            11.2.1.8. Rest of Western Europe

        11.2.2. By Therapy

        11.2.3. By Stage

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy

        11.3.3. By Stage

        11.3.4. By End User

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Rest of Eastern Europe

        12.2.2. By Therapy

        12.2.3. By Stage

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy

        12.3.3. By Stage

        12.3.4. By End User

    12.4. Key Takeaways

13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Australia

            13.2.1.6. New Zealand

            13.2.1.7. Rest of APAC

        13.2.2. By Therapy

        13.2.3. By Stage

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy

        13.3.3. By Stage

        13.3.4. By End User

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Therapy

        14.2.3. By Stage

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapy

        14.3.3. By Stage

        14.3.4. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. The US

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Therapy

            15.1.2.2. By Stage

            15.1.2.3. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Therapy

            15.2.2.2. By Stage

            15.2.2.3. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Therapy

            15.3.2.2. By Stage

            15.3.2.3. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Therapy

            15.4.2.2. By Stage

            15.4.2.3. By End User

    15.5. Benelux

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Therapy

            15.5.2.2. By Stage

            15.5.2.3. By End User

    15.6. France

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Therapy

            15.6.2.2. By Stage

            15.6.2.3. By End User

    15.7. Germany

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Therapy

            15.7.2.2. By Stage

            15.7.2.3. By End User

    15.8. Italy

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Therapy

            15.8.2.2. By Stage

            15.8.2.3. By End User

    15.9. Nordic

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Therapy

            15.9.2.2. By Stage

            15.9.2.3. By End User

    15.10. Spain

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Therapy

            15.10.2.2. By Stage

            15.10.2.3. By End User

    15.11. The UK

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Therapy

            15.11.2.2. By Stage

            15.11.2.3. By End User

    15.12. Poland

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Therapy

            15.12.2.2. By Stage

            15.12.2.3. By End User

    15.13. Russia

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Therapy

            15.13.2.2. By Stage

            15.13.2.3. By End User

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Therapy

            15.14.2.2. By Stage

            15.14.2.3. By End User

    15.15. Malaysia

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Therapy

            15.15.2.2. By Stage

            15.15.2.3. By End User

    15.16. Singapore

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Therapy

            15.16.2.2. By Stage

            15.16.2.3. By End User

    15.17. Thailand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Therapy

            15.17.2.2. By Stage

            15.17.2.3. By End User

    15.18. Australia

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Therapy

            15.18.2.2. By Stage

            15.18.2.3. By End User

    15.19. New Zealand

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Therapy

            15.19.2.2. By Stage

            15.19.2.3. By End User

    15.20. GCC Countries

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Therapy

            15.20.2.2. By Stage

            15.20.2.3. By End User

    15.21. South Africa

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Therapy

            15.21.2.2. By Stage

            15.21.2.3. By End User

    15.22. Israel

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Therapy

            15.22.2.2. By Stage

            15.22.2.3. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Therapy

        16.3.3. By Stage

        16.3.4. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. AstraZeneca

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Bayer

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Bristol-Myers Squibb

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Ono Pharmaceutical Co. Ltd

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Hutchison Medipharma

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. LintonPharm

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Shanghai Henlius Biotech

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Sanofi

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Pfizer 

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Novartis AG

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Stage, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Stage, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Stage, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Western Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 15: Western Europe Market Value (US$ Million) Forecast by Stage, 2018 to 2033

Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Eastern Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 19: Eastern Europe Market Value (US$ Million) Forecast by Stage, 2018 to 2033

Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: APAC Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 23: APAC Market Value (US$ Million) Forecast by Stage, 2018 to 2033

Table 24: APAC Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: MEA Market Value (US$ Million) Forecast by Therapy, 2018 to 2033

Table 27: MEA Market Value (US$ Million) Forecast by Stage, 2018 to 2033

Table 28: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Stage, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Stage, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 17: Global Market Attractiveness by Therapy, 2023 to 2033

Figure 18: Global Market Attractiveness by Stage, 2023 to 2033

Figure 19: Global Market Attractiveness by End User, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Stage, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Stage, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 37: North America Market Attractiveness by Therapy, 2023 to 2033

Figure 38: North America Market Attractiveness by Stage, 2023 to 2033

Figure 39: North America Market Attractiveness by End User, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Stage, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Stage, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Therapy, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Stage, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Western Europe Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 62: Western Europe Market Value (US$ Million) by Stage, 2023 to 2033

Figure 63: Western Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Western Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 71: Western Europe Market Value (US$ Million) Analysis by Stage, 2018 to 2033

Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033

Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033

Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 77: Western Europe Market Attractiveness by Therapy, 2023 to 2033

Figure 78: Western Europe Market Attractiveness by Stage, 2023 to 2033

Figure 79: Western Europe Market Attractiveness by End User, 2023 to 2033

Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Eastern Europe Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 82: Eastern Europe Market Value (US$ Million) by Stage, 2023 to 2033

Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Stage, 2018 to 2033

Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033

Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033

Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 97: Eastern Europe Market Attractiveness by Therapy, 2023 to 2033

Figure 98: Eastern Europe Market Attractiveness by Stage, 2023 to 2033

Figure 99: Eastern Europe Market Attractiveness by End User, 2023 to 2033

Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: APAC Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 102: APAC Market Value (US$ Million) by Stage, 2023 to 2033

Figure 103: APAC Market Value (US$ Million) by End User, 2023 to 2033

Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: APAC Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 109: APAC Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 110: APAC Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 111: APAC Market Value (US$ Million) Analysis by Stage, 2018 to 2033

Figure 112: APAC Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033

Figure 113: APAC Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033

Figure 114: APAC Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 115: APAC Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 116: APAC Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 117: APAC Market Attractiveness by Therapy, 2023 to 2033

Figure 118: APAC Market Attractiveness by Stage, 2023 to 2033

Figure 119: APAC Market Attractiveness by End User, 2023 to 2033

Figure 120: APAC Market Attractiveness by Country, 2023 to 2033

Figure 121: MEA Market Value (US$ Million) by Therapy, 2023 to 2033

Figure 122: MEA Market Value (US$ Million) by Stage, 2023 to 2033

Figure 123: MEA Market Value (US$ Million) by End User, 2023 to 2033

Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: MEA Market Value (US$ Million) Analysis by Therapy, 2018 to 2033

Figure 129: MEA Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033

Figure 130: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033

Figure 131: MEA Market Value (US$ Million) Analysis by Stage, 2018 to 2033

Figure 132: MEA Market Value Share (%) and BPS Analysis by Stage, 2023 to 2033

Figure 133: MEA Market Y-o-Y Growth (%) Projections by Stage, 2023 to 2033

Figure 134: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 135: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 136: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 137: MEA Market Attractiveness by Therapy, 2023 to 2033

Figure 138: MEA Market Attractiveness by Stage, 2023 to 2033

Figure 139: MEA Market Attractiveness by End User, 2023 to 2033

Figure 140: MEA Market Attractiveness by Country, 2023 to 2033